Two New Promising Treatment Regimens for Gonorrhea
Atlanta, GA - Two new antibiotic regimens using existing drugs - injectable gentamicin in combination with oral azithromycin and oral gemifloxacin in combination with oral azithromycin - successfully treated gonorrhea infections in a clinical trial. The trial was conducted by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). The study was conducted to identify new treatment options in the face of growing antibiotic resistance.
The findings were presented by CDC’s Robert Kirkcaldy, M.D., the clinical trial's principal investigator, at the 20th Meeting of the International Society for Sexually Transmitted Diseases Research (ISSTDR) in Vienna, Austria. All drugs studied in the trial were Food and Drug Administration-approved and are available in the United States. This is the first clinical trial to evaluate them as combination therapy for gonorrhea.
Researchers found 100 percent effectiveness of the injectable gentamicin/oral azithromycin combination in curing genital gonorrhea infections, and 99.5 percent effectiveness of the oral gemifloxacin/oral azithromycin combination. Both combinations cured 100 percent of infections of the throat and rectum. However, many trial participants reported adverse effects from the drugs, mostly gastrointestinal issues.
“These trial results are an exciting step in the right direction in the fight against drug-resistant gonorrhea,” said Gail Bolan, M.D., director of CDC’s Division of STD Prevention. “But patients need more oral options with fewer side effects. It is imperative that researchers and pharmaceutical companies prioritize research to continue to identify new, effective, better-tolerated drugs and drug combinations.” Continue>
Posted in: Pharma | June 24, 2015